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Aims. To determine the association between treatment against diabetes mellitus (DM) and treatment with antiglaucomatous drugs
in the entire Danish population and to investigate the comorbidity between DM and its complications with antiglaucomatous
treatment. Methods. Retrospective nationwide cohort study with data over a 16-year follow-up period. The National Danish
Registry of Medicinal Products Statistics was used to identify all claimed prescriptions for antiglaucomatous medication and DM
drugs. ICD-10 classifications were furthermore used to identify comorbidities between antiglaucomatous medication and the DM
complications, diabetic retinopathy (DR), and nephropathy. Results. A total of 6,343,747 individuals in the period between 1996
and 2012 were analyzed.The overall incidence rate of new-onset glaucoma patients was 0.07 per 1000 person-years for the reference
population compared to 36 per 1000 person-years for all diagnosed DM cases. Patients treated with DM drugs had about two
times higher relative risk of glaucoma, when adjusting for a range of factors. The presence of DR alone or in combination with
nephropathy increased the risk of glaucoma. Conclusions. The present study reports a strong association between DM and onset of
glaucoma treatment in the entire Danish population.
1. Introduction
Diabetic retinopathy (DR) is the most common late compli-
cation of diabetes mellitus (DM) in the working-age popula-
tion and one of the leading causes of blindness in the elderly,
accounting for a significant drop in quality of life (QoL)
and working ability for the patients [1–3]. Nonproliferative
DR presents clinically as superficial retinal hemorrhages,
cotton wool spots, or microvascular abnormalities [4–6].
Even so, proliferative diabetic retinopathy (PDR) can remain
asymptomatic for a very long time [6], and in that light,
patients with DM in Denmark are therefore monitored
closely by ophthalmologists annually.
The lack of oxygen in the retina causes fragile blood
vessels to grow into the vitreous body and along the retina,
causing an eminent risk of bleeding and formation of
fibrovascular/proliferative membranes, leading consequently
to tractional retinal detachment.These new blood vessels can
furthermore grow into the angle of the anterior chamber and
cause neovascular glaucoma [5].
To date, numerous screening studies have addressed the
question of whether DM is a risk factor for primary open
angle glaucoma (POAG); however, no converging or uniform
conclusions exist to date. Some studies state that POAG
is more prevalent in diabetic than in nondiabetic popula-
tions [7–12], while others found no statistically increased
correlation between the two, although being based on small
population sizes and yet raising themain reasonable question
concerning patient referral and bias associated with it [9, 13–
15]. A recent cohort study from the Tayside region of Scotland
included a population of 175,211 participants over a 2-year
period and found a relative risk of 1.57 for POAG and 1.38 for
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elevated eye pressure compared to the rest of the population,
although the results were not statistically significant [16].
The aim of the present study was to use data from the
entire Danish population using redeemed prescription on
antidiabetic and antiglaucoma drugs over a 16-year period
and check whether DM is a risk factor for developing
glaucoma after adjusting for diabetic complications and
several other demographic factors. Furthermore, we wanted
to investigate whether any difference exists in glaucoma
with regard to medication type, diabetic complications, or
concomitant medications such as antihypertensive drugs in
patients having DM.
To the best of our knowledge, only one previous cohort
study on the topic has been carried out to date, and no study
has addressed the association between the medication used
within the group of DM patients and patients treated with
antiglaucomatous medication. Moreover, the large dataset,
amounting to a 16-year follow-up of more than 6 million
individuals, constitutes a comprehensive source of data for
investigating comorbidities between DM and glaucoma.
2. Methods
2.1. Registers and Study Population. The study population
comprised all individuals living in Denmark in the period
between 1996 and 2012 and without previously diagnosed
DM or glaucoma, amounting to 6,343,747 individuals. Data
from the National Danish Civil Registration System contain
information on vital status of all individuals born in, or
migrating to, Denmark [17, 18]. In a subpart of the analysis,
the sample was restricted to individuals only prescribed
antidiabetic medication(s) and, within that group, patients
aged 40 to 100 years, thus focusing on age-dependent rather
than congenital disorders.The healthcare system inDenmark
is fully tax financed and equally available to all inhabitants
independent of social and financial status, and the Danish
government is responsible for collecting this high-quality,
nationwide healthcare data.
The information contained in the database contains dates
of redemption of antidiabetic or antiglaucomatous medi-
cation (if any) for each individual and furthermore data
on patients diagnosed with diabetic complications such as
DR and/or nephropathy. The diabetic complications were
identified based on the diagnostic codes, according to
the International Statistical Classification of Diseases and
Related Health Problems (ICD-10), and were retrieved from
the register accordingly. On the other hand, the incident
glaucoma and DM were based upon the pharmacotherapy
used, and glaucoma and DM information was retrieved
from the Danish Register of Medicinal Product Statistics,
which holds data on all prescriptions dispensed in Denmark
that are classified according to the Anatomical Therapeutic
Classification system; this register is directly linked to the
government for reimbursement purposes and is therefore
very accurate. All pharmacies inDenmark are required by the
government-financed Danish healthcare system to register
all redeemed prescriptions at the individual level by the
Danish Personal Identification number (the so-called CPR-
number). We hereby identify individuals taking antidiabetic
therapy through the National Danish Registry of Medicinal
Products Statistics. Drugs administered during a hospital
admission are, however, not included. Our data contain the
dates of all redeemed antidiabetic treatments as well as all
antiglaucomatous treatments, excluding those from before
1995, when mixed data on new and old prescriptions was
combined in the register. To assure that the data only contain
new prescriptions, all prescriptions registered in the database
after January 1, 1996, were therefore included in the study.
2.2. Definition of Pharmacotherapy and Comorbidity. DRwas
identified using ICD-10 and diagnosed as DH36, DH368,
DH360H, DH360J, DH360K, DH368D, DH368D1, and
DH368D2.
Diabetic nephropathy was identified using ICD-10 and
diagnosed as DE103, DE112, DE132, DE142, DN083, DN083,
DN251, and DN.
Glaucoma, for the present study, was identified accord-
ing to the following ACT codes for glaucoma medication:
use of 𝛽-blockers (S01ED01-05); prostaglandin analogues
(S01EE); 𝛼2-adrenergic agonists (S01EA); parasympathomi-
metic drugs (S01EB); carbon anhydrase inhibitors (S01EC);
fixed combination drugs (S01EA51, S01EB51, and S01ED51).
Patients were defined as having glaucoma if they received at
least 2 prescriptions within 90 days for at least one type of
antiglaucomatous medication.
Hypertension as comorbidity was used in a subset of the
analysis. Hypertension is most often managed by patients’
primary physicians, and so the in-hospital ICD-10 diagnosis
for essential hypertension (ICD-10I10) is used irregularly.
Therefore, identification of hypertensive patients in the stud-
ied population was validated by an algorithm (with a positive
predictive value of 80.0% and sensitivity of 94.7%), based
upon the use of at least 2 classes of antihypertensive drugs
(𝛽-blockers (BB), renin-angiotensin system (RAS) inhibitors,
calcium antagonists (Ccb), or diuretics (DD) and vasopro-
tectives (VP)) [19]. Patients treated with all drugs types were
excluded from the study due to lack of relevant controls.
The ATC codes for antihypertensive drugs used in the
analyses are listed here by classes of origin: BB are in the
group of C07; RAS inhibitors are in the group of C09; DD
are in the group of C03; Ccb are in the group of C08D, and
vasoprotectives are in the group of C02. To investigate the
effect of pharmacotherapy, the focus was placed on RAS and
BB, compared to the rest.
Patients were classified as incident with glaucoma (having
their onset of glaucoma) by their first redemption of an
antiglaucoma medication and incident with hypertension
(having their onset of hypertension) by their first redemption
of a second antihypertensive drug.
The selection process for the study population is illus-
trated in Figure 1.
2.3. Rationale for Definitions. DM and glaucoma are most
oftenmanaged and diagnosed by patients’ primary physicians
and an out-of-hospital specialist in ophthalmology, respec-
tively.Therefore, the in-hospital ICD-10 diagnoses for the two
diseases are not relevant. Instead, we identify the population
of glaucoma patients and those with DM and hypertension
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Danish population
January 1, 1996–December 31, 2012
N = 6,343,747
Antidiabetic medication
N = 277,268
Antidiabetic medication
Age > 40 years
N = 238,671
Diabetic retinopathy, N = 18,170
Diabetic nephropathy, N = 10,429
Hypertension, N = 133,169
Diabetic retinopathy, N = 14,535
Diabetic nephropathy, N = 9,767
Hypertension, N = 129,885
Figure 1: Flowchart of diabetesmellitus and glaucoma in theDanish population in the period from 1996 to 2012.TheNationalDanish Registry
of Medicinal Products Statistics was used to identify all individuals who were treated with glaucoma medication and/or antidiabetic drugs.
using the National Danish Registry of Medicinal Products
Statistics as descripted above.With this approach, we are able
to identify patients with a redeemed prescription for DM
and/or glaucoma. Furthermore, this procedure allows us to
identify the onset of the condition.
In patients who redeemed antidiabetic medication,
comorbidity with hypertension was then identified using a
validated algorithm based on the use of at least two classes
of antihypertensive drugs. This algorithm is shown to have
a tremendous sensitivity of 94.7% and a positive predictive
value of 80.0% [19], meaning that our validation algorithm
precisely identifies individuals with hypertension.
The Danish Civil Registration System contains informa-
tion about dates of birth and death of all Danish citizens since
1972 [18], while the Danish Registry of Medicinal Products
Statistics contains data on all prescriptions dispensed in Den-
mark since 1995, including information about size of doses,
quantity dispensed, and dispensing date. Prescriptions are
classified according to the AnatomicalTherapeutic Chemical
(ATC) System [17].
2.4. Statistical Analysis. To describe the evolution of the
incidence of DM,DR, and glaucoma, the incidence rates were
calculated in 5-year age strata, as a function of time, and
then summarized as events per 1,000 person-years at risk.
Furthermore, duration analysis models, based on the Poisson
distribution, were employed to investigate the associations
between DM treatments and DR, as well as the risk of
developing glaucoma, adjusted for a range of potentially
confounding factors.
The baseline characteristics are presented as means with
standard deviations or frequencies and percentages accord-
ingly. DM was considered to be a time-dependent variable
and thus subjects who developedDMcontributed risk time in
the reference group until the time of diagnosis. Comorbidity
was updated continuously throughout the follow-ups.Hazard
ratios (HRs) for the study endpoint were estimated using Cox
proportional hazards models adjusted for confounding fac-
tors including age, sex, comorbidity with DR, hypertension
(concomitant medications with antihypertensive drug(s)),
and diabetic nephropathy.
The primary analysis was not adjusted for medications
used for the treatment of hypertension. An additional anal-
ysis was carried out with inclusion of antihypertensives
when investigating all patients redeemed with antidiabetic
medication to estimate its impact on the HRs of glau-
coma. All statistical analyses were performed using SAS
9.4. Heteroscedasticity-robust standard errors were used
in the duration model and cluster-robust standard errors,
clustered on the individual level, were used in the regression
discontinuitymodels. A significance level of 0.05 was applied,
meaning that estimated coefficients with 𝑝 < 0.05 were con-
sidered statistically significant and 95% confidence intervals
were also reported.
2.5. Definitions. The incidence in a given year is defined as
the number of new cases in that year divided by the number
of individuals living in that year. The incidence rate is the
number of new cases over the 16-year study period per popu-
lation at risk (measured in 100 person-years).The relative risk
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Figure 2: Incidence of diabetes mellitus, diabetic retinopathy, and glaucoma in the Danish population, in the period from 1996 to 2012, per
1000 individuals (‰). (a) Diabetes mellitus incidence. (b) Diabetic retinopathy incidence. (c) Glaucoma incidence.
(RR) of developing glaucoma is the probability of developing
glaucoma for a certain group (e.g., males or individuals with
DM) divided by the probability of developing glaucoma for
the converse group.The estimates of the duration analysis are
converted to RR estimates by calculating their antilogarithm.
2.6. Outcome. Theprimary outcome in the present study was
glaucoma (as inferred by antiglaucomatous drug prescrip-
tions used).
2.7. Ethical Aspects. The Danish Data Protection Agency
approved the study (2007-58-0015, int. ref: GEH-2010-001).
Retrospective register-based studies do not require ethical
approval in Denmark.
3. Results
3.1. Baseline Characteristics of the Studied Population. The
study comprised a total of 6,343,747 subjects within a sixteen-
year follow-up. During the study period, 275,078 subjects
with incident DM, 75,022 subjects with incident glaucoma,
and 18,170 subjects with DR were identified, as shown in
the flowchart of the study population selection (Figure 1).
The average age at onset for DM was 59.19 years (range: 1.42
to 109.57 years), for DR 56.87 years (range: 4.99 to 98.74
years), and for glaucoma 69.31 years (range: 2.01 to 105.07
years). Median follow-up time was 15.66 (SD 3.08) years and
15.86 (SD 3.33) years for the reference population and DM,
respectively. The mean duration from diagnosis of DM to
incidence of glaucoma was 4.1 (SD 3.51) years.
3.2. Incidence of DM, DR, and Glaucoma. The incidence of
DM, DR, and glaucoma in the Danish population over the
period from 1996 to 2012 is depicted in Figure 2. A constant
number of new glaucoma cases per year were identified in the
total period, whereas the amount of new DM cases per year
appeared to increase in the same period.
3.3. Incidence Rates for DM and Glaucoma. The results
showed an association between DM and the increased risk of
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Figure 3: Hazard ratios for glaucoma development in patients treated with antidiabetic drugs. A range of confounding factors, comorbidity,
concomitant medications factors, age, and gender are being adjusted for. The underlying data represents patients ≥ 40 years of age. For data
on the total diabetic population, see Table 2. HR: hazard ratio; 𝑁: number of individuals; events: number of patients with glaucoma; CL:
confidence limit. ∗Significant on the 5% level. ∗∗Significant on the 1% level. ∗∗∗Significant at the 0.1% level.
new-onset glaucoma (Table 2).The overall incidence rates per
100 person-years were 0.070 (95% CI 0.069–0.071) and 0.36
(95% CI 0.35–0.37) for the reference population and patients
with DM, respectively. However, a common association with
age or other confounding factors may be the cause of such
an association. In particular, the risks of developing either
condition increase with age (Figure 3), which can potentially
explain this correlation.Therefore, we account for potentially
confounding factors in a duration model, presented in the
next subsection.
3.4. Duration Analysis. To exclude that increased incidence
of glaucoma among patients treated with antidiabetic medi-
cation is simply caused by a common association with age or
other potentially confounding factors, a duration model was
implemented.
Table 1 shows a series of duration models accounting
for various sets of potential covariates, namely, sex, age, and
calendar year fixed effects. The duration models estimate
the RR for developing glaucoma in patients treated with
antidiabetic drugs in the Danish population in the period
from 1996 to 2012. Column 1 presents the unconditional
association between DM and glaucoma. It establishes that
patients treated with antidiabetic drugs have a significantly
higher risk of glaucoma compared to people who never
redeemed prescriptions of antidiabetic drugs (RR = 5.13,𝑝 <
0.0001). Column 2 establishes that patients having DR have
a significantly higher risk of glaucoma compared to people
who do not have DR (RR = 4.69, 𝑝 < 0.0001). Column
3 indeed shows that use of antidiabetic drugs (RR = 5.11,
𝑝 < 0.0001) and DR (RR = 1.93, 𝑝 < 0.0001) have an
increased risk for glaucoma. The model further accounts in
column 4 for the gender of the individuals and establishes
that the RR of glaucoma in the DM and DR patients is still
above unity (RR = 5.16, 𝑝 < 0.0001 and RR = 1.54, 𝑝 <
0.0001, resp.), with a significantly higher risk of glaucoma in
6 Journal of Diabetes Research
Table 1: Duration analysis.The table shows the relative risk for developing glaucoma in patients treated with antidiabetic drugs in the Danish
population (1996–2012). The model controls for complication with DR and age as well as calendar year fixed effects (omitted from the table).
RR: relative risk; CI: confidence interval; anti-DM drug: antidiabetic drug.
Model
1
RR
(95% CI)
2
RR
(95% CI)
3
RR
(95% CI)
4
RR
(95% CI)
5
RR
(95% CI)
6
RR
(95% CI)
Anti-DM drug
(Reference: no anti-DM drugs)
5.13∗
(4.99–5.28)
5.11∗
(4.97–5.25)
5.16∗
(5.02–5.31)
1.81∗
(1.76–1.86)
2.05∗
(1.57–2.68)
DR
(Reference: no DR)
4.69∗
(3.67–6.00)
1.93∗
(1.51–2.46)
1.97∗
(1.54–2.52)
1.86∗
(1.46–2.38)
1.82∗
(1.42–2.33)
Gender
(Reference: males)
1.35∗
(1.33–1.37)
1.17∗
(1.15–1.18)
1.16∗
(1.15–1.18)
Age No No No No Yes Yes
Calendar year No No No No No Yes
∗
𝑝 < 0.001.
women (RR = 1.35, 𝑝 < 0.0001). Column 5 establishes that
treatment with antidiabetic drugs is still associated with an
increased risk of glaucoma while accounting for age (as five-
year age group fixed effects) in addition to sex (RR = 1.81,
𝑝 < 0.0001) and diagnosed DR (RR = 1.86, 𝑝 < 0.0001).
Finally, column 6 establishes that antidiabetic drugs are still
significantly associated with glaucoma while accounting for
calendar year fixed effects in addition to the other control
variables (RR = 2.05, 𝑝 < 0.0001).
3.5. Hazard Ratios of New-Onset Glaucoma in Patients with
DM. Using multivariate Cox regression model analyses, all
individuals treated with antidiabetic drugs were investigated
for the HR and adjusted for age, sex, comorbidity, concomi-
tantmedications, all being factors which can potentially affect
the risk of glaucoma.
In Table 2, the HR for a range of factors is shown
for all individuals, as well as for patients ≥ 40 years of
age. The latter regression results are illustrated in Figure 3.
Overall, an increased HR for glaucoma is found in patients
having DR, concomitant DR, and diabetic nephropathy and
hypertension. Furthermore, we confirm the above reported
substantial age-dependence, whereas the observed gender
difference is not statistically significant in this specification.
The results also show that patients treated with sulfony-
lureas, glitazone, and slow-acting insulin in combination
with rapid-acting insulin have a significantly higher HR
for developing glaucoma compared to patients treated with
rapid-acting insulin analogues (Table 2). Following up on
the reported increased HR in patients having concomitant
antihypertensive medication, the differences in the type
of antihypertensive medication in patients with DM were
investigated (Table 2, columns 2 and 4). Indeed, the type
of antihypertensive medication used has a significant effect,
while a combination of BBwith RAS analogues seems to have
a proactive effect. Furthermore, RAS and other antihyper-
tensive drugs have a significant increased effect, while BBs
in combination with one other antihypertensive medicament
have a tendency to lower the risk of glaucoma, although not
significantly from that of having no hypertension at all.
4. Discussion
To the best of our knowledge, the present study is one
of the largest studies investigating the association between
glaucoma and DM, using data for an entire population over
a sixteen-year period. We find an overall increased risk of
glaucoma among patients with DM.This association remains
evident when controlling for age, gender, retinopathy, and
year-specific fixed effects.
Furthermore, we find that, in patients with DM, comor-
bidity with hypertension as well as presence of DR and/or
joint complications with DR and nephropathy increases the
risk of glaucoma. However, treatment with the antihyperten-
sive combination of 𝛽-blockers and renin-angiotensin system
inhibitors appears to be associated with a significantly lower
hazard ratio for glaucoma onset in DM patients.
Other large population-based studies have also demon-
strated an association between glaucoma and DM [10–12,
20, 21], whereas the largest case-control study and cohort
study failed to find any association, explaining this lack of
association by a possible referral bias [9, 22].
Among studies which supported the association, the
Wisconsin study [12] found an odds ratio (OR) of 1.84 (95%
CI, 1.09–3.11), while the study from Australia [10] found an
OR of 2.12 (95%CI, 1.18–3.79), and the study fromRotterdam
[11] found an OR of 3.11 (95% CI, 1.12–8.66). An independent
study fromBaltimore foundno significant correlationwith an
ORof 1.03 (95%CI, 0.85–1.25) [9]. A recent cohort study from
Scotland further was lacking to find an association between
DM and glaucoma, when adjusting for age [16].
A number of studies have pointed to the possibility that
DM may affect the vascular autoregulation of retina and
the optic nerve and thereby promote the risk of DR and
glaucoma [20, 23, 24]. The present study reports a significant
correlation betweenDMand glaucoma, showing a higher risk
of glaucoma in patients treated with antidiabetic medication.
Adjusting for age and gender, the correlation is still signifi-
cant. In addition, adjusting for all year-specific fixed factors,
such as changes in public health policies or medical innova-
tions that may affect the treatment of both diseases, does not
change much the correlation between the two conditions.
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Table 2: Multivariable Cox regression model analyses showing the hazard ratios for glaucoma by antidiabetic drugs used in patients with
DM.The effect of complications such as diabetic retinopathy and nephropathy was investigated, as well as the concomitant medications used,
such as antihypertensive drugs. RAS: renin-angiotensin system; PE: parameter estimate; SE: standard error; HR: hazard ratio.
Model
Age ≥ 40 years All ages
1 2 3 4
PE
(SE) HR
PE
(SE) HR
PE
(SE) HR
PE
(SE) HR
DR
(Reference: no DR)
0.33∗∗∗
(0.08) 1.4
0.45∗∗∗
(0.04) 1.57
0.34∗∗∗
(0.07) 1.4
0.44∗∗∗
(0.04) 1.55
Diabetic nephropathy −0.02(0.14) 0.98
0.11∗
(0.05) 1.12
0.03
(0.13) 1.03
0.13∗∗
(0.05) 1.14
Hypertension
(Reference: no antihypertensives)
0.06
(0.03) 1.06
0.11∗∗
(0.03) 1.12
Gender
(Reference: males)
−0.01
(0.03) 0.99
−0.01
(0.03) 0.99
0
(0.03) 1
0
(0.03) 1
Nephropathy × DR 0.34
∗∗
(0.12) 1.4
0.34∗∗
(0.11) 1.41
Nephropathy × hypertension 0.05(0.15) 1.05
0.01
(0.14) 1.01
DR × hypertension 0.1(0.09) 1.1
0.08
(0.09) 1.08
Biguanides 0.17(0.16) 1.18
0.17
(0.16) 1.19
0.24
(0.14) 1.27
0.24
(0.14) 1.28
Combination 0.64
∗
(0.33) 1.91
0.66∗
(0.33) 1.93
0.71∗
(0.32) 2.04
0.73∗
(0.32) 2.07
GLP-1-analogues and DDP-IV-inhibitors −0.05(0.52) 0.95
−0.05
(0.52) 0.96
0.26
(0.47) 1.3
0.27
(0.47) 1.31
Glitazones 1.32
∗∗
(0.47) 3.73
1.31∗∗
(0.47) 3.72
1.36∗∗
(0.47) 3.88
1.36∗∗
(0.47) 3.89
Insulin and insulin analogues (slow) 0.55(0.41) 1.74
0.57
(0.41) 1.77
0.47
(0.4) 1.59
0.48
(0.4) 1.62
Insulin and insulin analogues (slow
combined with rapid)
0.4∗
(0.18) 1.49
0.4∗
(0.18) 1.49
0.47∗∗
(0.16) 1.59
0.47∗∗
(0.16) 1.6
Insulin and insulin analogues (intermediate) 0(0.18) 1
0.01
(0.18) 1.01
0.12
(0.16) 1.13
0.13
(0.16) 1.14
Meglitinides 0.27(0.19) 1.31
0.27
(0.19) 1.31
0.35∗
(0.18) 1.43
0.36∗
(0.18) 1.43
Sulphonylurea 0.29(0.16) 1.34
0.3
(0.16) 1.35
0.4∗∗
(0.14) 1.49
0.4∗∗
(0.14) 1.5
𝛼-Glucosidase inhibitors 0.21(0.29) 1.24
0.21
(0.29) 1.24
0.33
(0.28) 1.4
0.34
(0.28) 1.4
RAS + 𝛽-blocker −0.14
∗∗
(0.06) 0.87
−0.09
(0.06) 0.92
RAS + antiadrenergic 0.52
∗∗
(0.18) 1.68
0.56∗∗
(0.18) 1.75
RAS + Ccb 0.19
∗∗∗
(0.05) 1.21
0.23∗∗∗
(0.05) 1.25
RAS + Diu 0.16
∗∗∗
(0.04) 1.18
0.21∗∗∗
(0.04) 1.24
RAS + Vas 0.23(0.13) 1.26
0.24∗
(0.13) 1.28
RAS 𝛽-blocker + 1 other −0.03(0.07) 0.97
0.01
(0.07) 1.01
RAS + (other ≥ 2) 0.11(0.09) 1.12
0.17∗
(0.08) 1.18
𝛽-Blocker + other antihyp. drugs ≥ 1 −0.03(0.05) 0.97
0.03
(0.05) 1.03
Other antihyp. drugs ≥ 2 0.09(0.05) 1.09
0.15∗∗
(0.05) 1.16
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Table 2: Continued.
Model
Age ≥ 40 years All ages
1 2 3 4
PE
(SE) HR
PE
(SE) HR
PE
(SE) HR
PE
(SE) HR
Age 50–59 years
(ref 40–49)
0.48∗∗∗
(0.06) 1.62
0.49∗∗∗
(0.06) 1.63
Age 60–69 years
(ref 40–49)
0.9∗∗∗
(0.06) 2.46
0.91∗∗∗
(0.06) 2.48
Age 70–79 years
(ref 40–49)
1.15∗∗∗
(0.06) 3.16
1.16∗∗∗
(0.06) 3.19
Age > 80 years
(ref 40–49)
1.11∗∗∗
(0.07) 3.03
1.12∗∗∗
(0.07) 3.06
Age 21–40 years
(ref < 21)
1.07∗∗
(0.3) 2.91
1.08∗∗
(0.3) 2.95
Age 41–60 years
(ref < 21)
2.33∗∗∗
(0.3) 10.25
2.34∗∗∗
(0.3) 10.39
Age 61–80 years
(ref < 21)
2.96∗∗∗
(0.3) 19.25
2.98∗∗∗
(0.3) 19.6
Age > 80 years
(ref < 21)
3.04∗∗∗
(0.3) 20.8
3.06∗∗∗
(0.3) 21.23
Number of individuals 238,671 238,671 277,266 277,266
∗
𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗𝑝 < 0.001.
Although our results indicate a strong association
between use of DM drugs and the use of antiglaucomatous
drugs, we cannot rule out the possibility that the observed
association is affected by the fact that patients with DM may
get eye diseases detected more often by routine clinical care
compared to healthy individuals.
As an additional finding, the present study finds an
increased risk of glaucoma among DM patients with DR
and/or joint complications with DR and nephropathy. The
mechanisms behind this association could simply be that
these patients suffer from a more severe DM disease. Both
DR and nephropathy are serious conditions that need inten-
sive treatment. Furthermore, diabetic nephropathy is often
treated with ACE inhibitor as well as lipid lowering treatment
and aspirin.
A possible increased risk of glaucoma in patients with
concomitant hypertension and DM was further investigated.
Overall, we show that antihypertensive medication is asso-
ciated with an increased risk of glaucoma in patients with
DM. However, the combination of 𝛽-blocker and renin-
angiotensin system inhibitors appears to lower the haz-
ard ratio for glaucoma onset in DM patients. In general,
inhibitors of the renin-angiotensin system (RAS) are a com-
monly used medicament in treatment of hypertension. In
addition to regulate blood pressure, RAS is an active local
system in the eye [25–28] (1–7) and ACE is found to be
significantly higher in glaucomatous eyes [25]. The literature
highlights the importance of particularly angiotensin II in
the etiology of eye diseases. Some studies have shown that
ACE inhibitor reduces the IOP and have a protective effect
against glaucoma [29–31], but it has also been shown that the
peptide angiotensin II is a modulator or transmitter in retinal
neurophysiology. Thereby, an inhibition of ACE results in a
decrease in angiotensin II that might cause disturbance of
retinal neuronal function [28, 32]. Furthermore, a counter-
balancing interaction between ACE II products and ACE-
I has been suggested to be important [27, 33]. Our study
indicates that inhibition of the RAS either increases the risk
of glaucoma or reflects a more severe form of DM. However,
we find that patients receiving a combination of RAS and
BB have a significantly lower risk of glaucoma compared to
DM patients without comorbidity with hypertension. One
explanation for the decreased risk in patients treated with BB
could be the intraocular pressure-lowering effect of this drug
[34]. In our study, we reveal that RAS is generally positively
associated with glaucoma, except in the combination with
BB. We believe that this difference in associations can be due
to either a preventive effect of BB or a synergistic effect of
RAS and BB. Further studies are needed to disentangle these
possible mechanisms. If this observed association is proven,
it may suggest that RAS treated patients with DMwould need
further attention for diagnosis or treatment of glaucoma.
The main strength of our study is the use of compre-
hensive data resources covering a large population base,
namely, the entire Danish population followed over 16 years.
In particular, theNationalDanishRegistry records 100%of all
dispensed prescriptions in all pharmacies in Denmark, and,
furthermore, all births, deaths, emigrations, and immigra-
tions in Denmark. However, a limitation of the study is that
we use prescriptions as the indicator of glaucoma andDM. In
this matter, we are not able to conclude anything concerning
the etiology or severity of the conditions.
In conclusion, this study reports an increased risk of
glaucoma among patients treated with antidiabetic drugs.
Furthermore, comorbiditywithDR and the joint comorbidity
with DR and/or diabetic nephropathy increase the hazard of
getting glaucoma. Concomitant medications such as antihy-
pertensive drugs can also increase the hazard for developing
Journal of Diabetes Research 9
glaucoma. However, particular treatment with BB decreases
the risk of glaucoma, while combination of BB and RAS
conversely increases the risk.
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